Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around
Principal Investigator
by Michelle Van Kuiken, MD

Description

Summary

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Official Title

Sacral Neuromodulation for Male Overactive Bladder

Details

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).

Keywords

Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency, Overactive Urinary Bladder, Prostatic Hyperplasia, Prostatic Neoplasms, Axonics SNM System, Post-prostatectomy, Radiation, Benign Prostatic Hyperplasia (BPH)

Eligibility

You can join if…

Open to males ages 18 years and up

  1. Participants aged ≥ 18 years at the time of enrollment
  2. Able to complete bladder diaries and patient questionnaires
  3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).
  4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year

You CAN'T join if...

  1. Any patient that is not a suitable candidate per investigator discretion
  2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment
  3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
  4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices
  5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)
  6. Positive response to Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment
  7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician
  8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the discretion of the participating physician.
  9. Uncontrolled diabetes
  10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • USNC accepting new patients
    Mountain View California 94040 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Axonics, Inc.
ID
NCT06511141
Study Type
Interventional
Participants
Expecting 150 study participants
Last Updated